OmniAb Inc. (OABI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $716.17M
Last updated: Nov 17, 2026 at 11:06 AM ET
OmniAb Inc. (OABI) Competitors
The companies most similar to OmniAb are Avalo Therapeutics (AVTX), Omeros (OMER) and Olema Pharmaceuticals (OLMA). By market cap, OmniAb ranks 5th of the 13 companies on this page; Omeros (OMER) is the largest at $1.27B.
Peer Comparison
OABI's ROIC of -17.5% is above the peer median of -30.9%, and its revenue growth of 78.3% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| OmniAb (OABI) | $716.17M | N/A | 15.7x | -108.1% | -17.5% | 78.3% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Omeros Corporation (OMER) | $1.27B | N/A | 16.4x | 324.9% | 33.6% | 14.9% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Annexon Inc (ANNX) | $747.79M | N/A | N/A | 0.0% | -84.6% | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Surrozen Inc (SRZN) | $602.54M | N/A | 36.1x | 0.0% | N/A | 408.6% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $631.18M | N/A | 36.1x | 0.0% | -30.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to OmniAb, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Omeros Corporation (OMER) | Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies... | OMER competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Annexon Inc (ANNX) | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. | ANNX competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Surrozen Inc (SRZN) | Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform... | SRZN competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
Frequently Asked Questions About OABI
Who are OmniAb's main competitors?
The companies most similar to OmniAb include Avalo Therapeutics (AVTX), Omeros (OMER), Olema Pharmaceuticals (OLMA), Annexon (ANNX) and Immix Biopharma (IMMX), listed from the closest match.
Who is OmniAb's biggest competitor?
Omeros (OMER) is the largest of the similar companies at $1.27B; Avalo Therapeutics (AVTX) is the closest match by business profile, size, sector and industry.
How does OABI stock compare with its competitors?
OABI's P/S is 15.7x against a peer median of 36.1x; its net margin is -108.1% against a peer median of 0.0%.
Which of OmniAb's competitors pays a higher dividend?
OmniAb pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is OmniAb bigger than its competitors?
No. OmniAb is 5th by market cap among the 13 companies on this page; the largest is Omeros (OMER) at $1.27B.
OABI pages: Overview, Earnings, Forecast, Financials, Competitors